TAK — Takeda Pharmaceutical Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapSuper Stock

Annual cashflow statement for Takeda Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	44,290	376,171	230,166	317,038	144,197
Depreciation
Non-Cash Items	172,928	12,308	252,109	327,626	182,842
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-130,486	62,781	57,679	-331,908	-338,697
Change in Accounts Receivable
Change in Inventories
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	670,381	1,010,931	1,123,105	977,156	716,344
Capital Expenditures	-217,710	-236,468	-186,037	-633,689	-480,730
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	509,829	629,998	-12,088	26,587	16,868
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	292,119	393,530	-198,125	-607,102	-463,862
Financing Cash Flow Items	-132,804	-142,352	-108,592	-117,732	-126,478
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-1,005,213	-1,088,354	-1,070,265	-709,148	-354,416
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-64,479	328,608	-116,527	-316,165	-75,730